AEHR TEST SYSTEMS WKN: 908802 ISIN: US00760J1088 Forum: Aktien Thema: Hauptdiskussion

Moin Andy schön das du wieder mal auftauchst 😃 Ich habe "gehört", dass du dich aus den Foren zurückziehen willst bzw. diesen Schritt schon teilweise vollzogen hast. Was ist da dran ?

Mit breitem Grinsen dabei:-)

https://www.boerse-express.com/news/articles/aehr-test-aktie-starke-ergebnisse-trotz-herausforderungen-643032

Kneipe hat wohl noch offen 😮

Vergess den Rollator nicht 😜

ich ziehe eine Runde durch die Gemeinde 🍻.....bis morgen

Danke dir 🍻🍻

Ich traue mich jetzt nicht mehr, Glückwunsch euch. 🍻

neuer Angriff auf die 20$ ....da kommt noch was ....Spannung pur 🍻 🍻 🍻

Ich bin für heute zufrieden 😂 Darf morgen aber gerne weitergehen ;)

bin gespannt was der Videostream noch bringt ....an $$

Schade dass ich nicht mehr gekauft hatte 😂

After Hours Volume: 1M

200 x 1500€ reicht für ein Wohnmobil :-)

Aehr Test Systems Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Provides Fiscal 2025 Full Year Financial Guidance 07/16/2024 FREMONT, CA / ACCESSWIRE / July 16, 2024 / Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced financial results for its fiscal 2024 fourth quarter and full year ended May 31, 2024. Fiscal Fourth Quarter Financial Results: Net revenue was $16.6 million, compared to $22.3 million in the fourth quarter of fiscal 2023 GAAP net income was $23.9 million, or $0.81 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million, compared to GAAP net income of $6.1 million, or $0.21 per diluted share, in the fourth quarter of fiscal 2023. Non-GAAP net income was $24.7 million, or $0.84 per diluted share, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, compared to non-GAAP net income of $6.8 million, or $0.23 per diluted share, in the fourth quarter of fiscal 2023. Bookings were $4.0 million for the quarter Backlog as of May 31, 2024, was $7.3 million. Effective backlog, which includes all orders received since the end of the fourth quarter, is $20.8 million. Total cash and cash equivalents as of May 31, 2024 were $49.2 million, up from $47.6 million at February 29, 2024 Fiscal Year Financial Results: Net revenue was a record $66.2 million, compared to $65.0 million in fiscal 2023 GAAP net income was $33.2 million, or $1.12 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million recognized in the fourth quarter, compared to GAAP net income of $14.6 million, or $0.50 per diluted share, in fiscal 2023. Non-GAAP net income, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, was $35.8 million, or $1.21 per diluted share, compared to non-GAAP net income of $17.3 million, or $0.59 per diluted share, in fiscal 2023. An explanation of the use of non-GAAP financial measures and a reconciliation of Aehr's non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying tables.

3 Jahre halten und mit lächerlichen 200 stück in Rente gehen^^?